Abstract
Introduction and Aims
Crohn's disease is a chronic inflammatory bowel disease with a broad spectrum of clinical manifestations and variable outcome. Historically, Crohn's disease was believed to be an ileocaecal disorder, potentially cured by radical surgery. With time it became clear that the inflammation could affect the entire gastrointestinal tract and that recurrence of disease was common even after extensive surgery. Medical therapy advanced with the use of immunomodulators and the introduction of biologics. Changes in medical therapy and surgical practice over time might have influenced the natural history of the disease and possibly reduced surgery rates (1) (2) (3) (4) (5) (6) (7) . However, epidemiological studies that have evaluated the effect of immunomodulators on surgery rates have yielded conflicting results (7) (8) (9) .
Recent clinical trials have also questioned the effect of immunomodulators as primary prophylaxis to reduce the need for surgical resections (10, 11) .
The risk of progression towards complicated disease behaviour with strictures and/or fistulas and need of surgery might be influenced by factors other than medication. Time from onset of symptoms until diagnosis and initiation of treatment, that is diagnostic delay, has been associated with increased risk of stricturing disease and surgery (12) . We have previously reported an increasing proportion of patients with non-stricturing, non-penetrating behaviour at diagnosis over time, pointing towards an earlier diagnosis or change in disease phenotype (13) . Whether patients with non-stricturing, non-penetrating behaviour at diagnosis can avoid future disease complications necessitating surgery by adequate medical anti-inflammatory therapy is unknown. If so, this could possibly influence the rates of surgery in patients with Crohn's disease over time. However, whether the risk of disease progression to complicated disease behaviour depends on the time period of diagnosis is unknown.
Our aim was to explore changes in the short-term natural history of Crohn's disease over time. More specifically, we wanted to assess trends in disease phenotype, medication and surgery in patients diagnosed with Crohn's disease within a well-defined population-based cohort in Sweden between 1963 and 2005, with patients followed for five years from diagnosis.
Materials and Methods

Study area and patient population
The primary catchment area of Örebro University Hospital includes a mix of urban and rural and 31 st of December 2005 (n=472) and has been described previously in detail (13) . In short, patients of all ages with a diagnosis of CD were identified retrospectively by evaluation of medical records of all current and previous patients at the colitis clinic, Örebro University Hospital, and amended by computerised search in the inpatient, outpatient, primary care and histopatological records. Patients who died or left the area were censored on the date of death or emigration. Patients were divided into three cohorts based on the year of diagnosis: 1963-1975; 1976-1990; and 1991-2005 .
The Uppsala Regional Ethics Committee approved the study (2010/304).
Data collection
The medical records for all patients were reviewed by YZ and data on patient demographics, disease characteristics, drug treatments and any surgical procedures from diagnosis and during follow-up were collected using standardized questionnaires. Records for patients where clinical data were uncertain were jointly reviewed by YZ, CT and JH.
Description of variables
Patient demographics included age at diagnosis, date of diagnosis, sex, smoking status at diagnosis and date of death or emigration. Crohn's disease location and behaviour at diagnosis and during follow-up were classified according to the Montreal classification (14) . 
Results
Demographic information
The study included 472 patients within the primary catchment area of Örebro University
Hospital diagnosed with Crohn's disease from the 1st of January 1963 to the 31st of December 2005 (table 1) . Information on disease location and behaviour at diagnosis and follow-up was available for 469 (99.4%) patients. 
Change in location of Crohn's disease
Starting the observation period from day of diagnosis, and assuming ileocolonic (L3) disease occurring before or at diagnosis occurred on diagnosis day (day 0), the proportion of patients with ileocolonic (L3) disease at 5 years after diagnosis differed between the cohorts 
Surgery
In total, 196/472 (41.5%) patients had undergone surgery related to Crohn's disease at 5 years after diagnosis; details of the first surgery are presented in table 2. In 70 patients (14.8%),
Crohn's disease was diagnosed at the first surgical procedure. 
Discussion
A reduction in surgical rates has been reported in Crohn's disease during recent decades, potentially due to increased use of immunomodulators and biologics (8, 15, 16) . Especially early introduction of biologics seems to induce mucosal healing (17) (18) (19) (20) , thereby theoretically inhibiting progression towards complicated disease behaviour with strictures and fistulas and ultimately reducing the need of surgery. However, whether the observed decrease in surgery reflects entirely treatment effects remains largely unknown. In this large retrospective population-based study of patients diagnosed with Crohn's disease in 1963-2005 we confirm that the proportion of patients undergoing surgery within five years from diagnosis has decreased over time. The reduction in surgery preceded the widespread use of immunomodulators as well as the introduction of biologics. In parallel with the drop in surgery rates, a reduction in the proportion of patients with complicated disease behaviour during follow-up was observed. The difference in surgery rates over time seemed to be driven primarily by a decrease in early surgery within three months from diagnosis, reflecting the increasing proportion of patients with non-stricturing, non-penetrating (B1) disease at diagnosis (13) . These novel findings suggest that the introduction of new treatments alternatives alone do not explain the decreasing surgical rates in Crohn's disease. Differences in the phenotypic presentation over time may also have played an important role.
Historically, Crohn's disease has been associated with a pronounced risk of surgery, with almost all patients undergoing surgery in their lifetime (21) (22) (23) (24) (25) . In our population-based cohort, the 5-year cumulative risk of Crohn's disease related surgery decreased from 65.8% to The decrease in surgery was not explained by an increased long-term corticosteroid use, since the 5-year cumulative probability of long-term corticosteroid treatment remained low (6-8%) throughout the study period. Higher rates of long-term corticosteroids have been reported from Cardiff, UK (29%) and Australia (59.2%), although the definition of long-term corticosteroids included budesonide, or was slightly different to our study (7, 15) Interestingly, the relative proportion of patients with non-stricturing, non-penetrating (B1) disease at diagnosis who progressed to complicated behaviour was stable during our study period. Thus, the difference in disease behaviour over time was explained entirely by our previously reported increased proportion of patients in non-stricturing, non-penetrating (B1) status at diagnosis (13) . Complicated disease behaviour is intimately associated with increased risk of surgery (32, 33) . Therefore, it seems likely that the decrease in surgery rates, and specifically early surgery, is explained by the observed increasing proportions of patients with non-stricturing, non-penetrating (B1) disease at diagnosis (13) . These findings probably reflect that patients are diagnosed earlier in their disease course today than in the past, and that this improves treatment outcomes in terms of surgery at five years after diagnosis. This theory is supported by the previous reported association between diagnostic delay and increased risk for surgery (12) . Improved diagnostic procedures leading to the identification of a subset of patients with non-stricturing, non-penetrating disease and a milder disease course might also have played a role, since we previously observed an increasing incidence over time in the cohorts (13) . Theoretically such a subgroup could have a very low need for surgery and might not have been diagnosed at such an early point in the disease course in the past. Increased access to specialist care within one year from diagnosis has also been associated with decreasing surgery rates over time (5) , and might also have contributed to the decrease in surgery rates, since the number of specialists increased during the study period (data not shown). Older age at diagnosis has also been associated with a milder disease and less need of surgery (34) . Therefore, the increase in non-stricturing, non-penetrating (B1) disease at diagnosis and the observed decrease in surgery within 5 years from diagnosis might be related to aging population structure. Together, these findings suggest that the introduction of new treatment alternatives alone do not explain the decreasing surgical rates in Crohn's disease (35, 36) , differences in disease phenotype at diagnosis, where patients seem to be diagnosed at an earlier stage, may also play an important role.
Permanent stoma formation is a consequence of severe longstanding treatment resistance, especially when accompanied by severe perianal disease, and a marker of decreased quality of life in Crohn's disease (37) . No difference was observed in the 5-year proportion of patients who received a permanent stoma during the study period. This finding is supported by a previous French report, where the proportion of patients receiving a permanent stoma within 5 years from diagnosis was stable in patients diagnosed with Crohn's disease at Rothschild hospital between 1978 and 2003 (9). However, it can only be speculated if the duration of follow-up was too short to observe such a difference, since permanent stoma often reflects an end-stage of the disease (38) . The proportion of patients that experienced progression from ileal or colonic disease to ileocolonic decreased during the study period. Theoretically, this temporal trend could be explained by improved clinical work-up at diagnosis and especially the introduction of new methods like magnetic resonance imaging, capsule endoscopy, ultrasound and high-resolution endoscopes. Alternatively, implementation of these techniques during follow-up, rather than at diagnosis, would have had the opposite effect, leading to a spurious indication of progression (39, 40) . To reduce the risk of bias, due to the introduction of these novel techniques in different years, upper gastrointestinal disease (L4) was regarded were 2.0% and 8.4% at 1 and 5 years, respectively, from diagnosis and are lower than in some earlier reports from referral centres. However, the time period represents the early years within the era of biologics, when the treatment strategies were yet to be established and biologics often introduced late during the disease course as a third-line treatment, and other population-based studies from these years have revealed similar figures (2, 5, 7, 8) . Therefore, the study was not designed to address the question of disease modification due to anti-TNF therapy.
The strengths of our study include the strict population-based design, allowing almost complete follow-up, and the thorough scrutiny of each patient's medical notes, providing information on disease phenotype, medical and surgical history at an individual level. The retrospective design is a potential limitation of the study. All diagnoses were re-assessed to reduce the risk of bias due to historical differences in diagnostic procedures and management.
However, differential bias by period might still have occurred, since perception of symptoms qualifying for referral to the Department of Gastroenterology might have differed over time (41, 42) . Furthermore, completeness in registration of patients with Crohn' disease may differ the cohorts, since computerised search of records was available from 1988 and onwards only.
Prescription dates do not necessarily reflect drug intake, therefore, start and termination dates might reflect approximate dates. Our study reports trends over time rather than associations between specific medications and outcomes like Crohn's disease related surgery or progression in disease behaviour. This was not performed as such analyses are prone to influence of confounding by indication, where patients with most severe disease course are those treated most aggressively.
In this large population-based study we observed a decrease in surgery and complicated disease behaviour as well as an increase in the use of immunomodulators at five years after diagnosis over time. The decrease in surgery and complicated disease behaviour preceded the increased use of immunomodulators and seemed to be explained by a decrease in early surgery within three months from diagnosis, reflecting the increasing proportion of patients with non-stricturing, non-penetrating (B1) disease at diagnosis.
Our novel findings suggest that the introduction of new treatment alternatives alone do not explain the decreasing surgical rates in Crohn's disease, differences in disease phenotype at diagnosis, where patients seem to be diagnosed at an earlier stage, also play an important role. 
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Supplementary data
Supplementary table 1. Proportion of patients and corresponding 95% CI with ileocolonic (L3) disease location in all patients irrespectively of location at diagnosis, and overall logrank test of equality of survivor functions between study cohorts on diagnosis day, one and five years from diagnosis.
Supplementary table 2.
Proportion of patients and corresponding 95% CI with progression from ileal (L1) or colonic (L2) disease to ileocolonic (L3) location and overall log-rank test of equality of survivor functions between study cohorts, one and five years from diagnosis. 29 complication (stricturing or penetrating disease whichever came first) in patients with nonstricturing non-penetrating disease at diagnosis, and overall log-rank test of equality of survivor functions between study cohorts one and five years from diagnosis.
Supplement table 5. Proportion of patients treated with immunomodulators with
corresponding 95% CI and overall log-rank test of equality of survivor functions between study cohorts at 1 year and 5 years from diagnosis. 
